Positive Outlook for Anixa Biosciences: Patent Secures Ovarian Cancer Vaccine and Promising CAR-T Therapy Progress

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, with a price target of $7.00.

Yi Chen has given his Buy rating due to a combination of factors including the recent announcement by Anixa Biosciences that the United States Patent and Trademark Office will issue a patent for their ovarian cancer vaccine technology. This patent secures the methods of administering a composition that elicits an immune response specific to the AMHR2 polypeptide, which is a significant step forward for the company. Anixa holds exclusive worldwide rights to this patent, which is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute, highlighting its potential to prevent and treat ovarian cancer, especially in high-risk groups.
Additionally, Yi Chen notes the progress in Anixa’s CAR-T therapy for ovarian cancer, which has recently dosed the first patient in the fourth cohort of its Phase 1 trial. The absence of dose-limiting toxicity in earlier cohorts and the trial’s expansion to include additional patient groups suggest a promising outlook for this therapy. The partnership with Moffitt Cancer Center and the potential for higher doses to increase treatment efficacy further support the positive rating. These developments underscore the potential for Anixa’s innovative therapies to make a significant impact in the treatment of ovarian cancer.